J. Blake Bartlett

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

Lei Wu, Mary Adams, Troy Carter et al. · Clinical Cancer Research · 2008 · 431 citations · Full text

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

Christine Galustian, B Meyer, Marie‐Christine Labarthe et al. · Cancer Immunology Immunotherapy · 2008 · 384 citations · Full text

Anti-cancer Agents, Cancer Immunosurveillance, Medicine +10

Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

Stephen Schey, Paul Fields, J. Blake Bartlett et al. · Journal of Clinical Oncology · 2004 · 309 citations · Full text

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

Keith Dredge, Rebecca Horsfall, Simon P. Robinson et al. · Microvascular Research · 2005 · 268 citations

Inflammation, Angiogenesis, Medicine +10

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

Ling Lu, Faribourz Payvandi, Lei Wu et al. · Microvascular Research · 2008 · 221 citations

Oncology, Angiogenesis, Anti-cancer Drug Lenalidomide +11